Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Gov't to Help Create Biobank to Support CARTaGENE Project

NEW YORK (GenomeWeb News) — The Canadian government yesterday said it will help create a biobank to store and manage biological samples collected by the nation’s CARTaGENE research projects, according to a participant.
The biobank was developed by Genome Quebec and the Centre de sante et de services sociaux de Chicoutimi, a hospital center affiliated with the University of Montreal.
It will be responsible for collecting and managing biological samples from the 20,000 Quebecois citizens participating in the CARTaGENE project, as well as other “key” projects, according to GenVault, which has been hired to “implement the system and technology” for archiving and retrieving the samples.
The biobank, which will receive CA$9.6 million ($9 million) in government financing over three years, will be housed in the Centre de sante et de services sociaux de Chicoutimi. According to GenVault, it will use $2 million of this cash to “adapt the premises needed to operate” and to support “quality jobs.”
According to Jean-Pierre Blackburn, minister of labor and economic development, the biobank will enable the Saguenay-Lac-Saint-Jean region in southern Quebec “carve out a prime place for itself among national and international genetic research networks and, in so doing, improve its international standing … [and] strengthen the ties between entrepreneurs and scientists.”
The biobank, which is Genome Quebec's fourth platform, further “aims to group advanced equipment financed by major projects in genomics and increase its availability to academic and private sector scientists,” added Paul L'Archeveque, President and CEO of Genome Quebec.
The bank will also become a “precursor” for other “large” biobanks, according to Claude Laberge scientific director of CARTaGENE.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.